AKTX vs. ONCT, COCP, ALRN, BNTC, TPST, ELDN, ANVS, CKPT, MNOV, and VHAQ
Should you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Oncternal Therapeutics (ONCT), Cocrystal Pharma (COCP), Aileron Therapeutics (ALRN), Benitec Biopharma (BNTC), Tempest Therapeutics (TPST), Eledon Pharmaceuticals (ELDN), Annovis Bio (ANVS), Checkpoint Therapeutics (CKPT), MediciNova (MNOV), and Viveon Health Acquisition (VHAQ). These companies are all part of the "pharmaceutical preparations" industry.
Oncternal Therapeutics (NASDAQ:ONCT) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.
Akari Therapeutics has lower revenue, but higher earnings than Oncternal Therapeutics.
In the previous week, Oncternal Therapeutics had 1 more articles in the media than Akari Therapeutics. MarketBeat recorded 1 mentions for Oncternal Therapeutics and 0 mentions for Akari Therapeutics. Akari Therapeutics' average media sentiment score of 0.00 equaled Oncternal Therapeutics'average media sentiment score.
16.1% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by company insiders. Comparatively, 38.9% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Oncternal Therapeutics presently has a consensus target price of $28.33, indicating a potential upside of 242.60%. Given Akari Therapeutics' higher probable upside, equities analysts plainly believe Oncternal Therapeutics is more favorable than Akari Therapeutics.
Akari Therapeutics received 232 more outperform votes than Oncternal Therapeutics when rated by MarketBeat users. Likewise, 54.36% of users gave Akari Therapeutics an outperform vote while only 31.58% of users gave Oncternal Therapeutics an outperform vote.
Oncternal Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Akari Therapeutics has a net margin of 0.00% compared to Akari Therapeutics' net margin of -3,160.73%. Oncternal Therapeutics' return on equity of 0.00% beat Akari Therapeutics' return on equity.
Summary
Akari Therapeutics beats Oncternal Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Akari Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akari Therapeutics Competitors List
Related Companies and Tools
